These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17764096)

  • 1. Cost-effectiveness analysis of a multinational RCT with a binary measure of effectiveness and an interacting covariate.
    Willan AR; Kowgier ME
    Health Econ; 2008 Jul; 17(7):777-91. PubMed ID: 17764096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical decision making and the expected value of information.
    Willan AR
    Clin Trials; 2007; 4(3):279-85. PubMed ID: 17715257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of group psychotherapy for depression in Uganda.
    Siskind D; Baingana F; Kim J
    J Ment Health Policy Econ; 2008 Sep; 11(3):127-33. PubMed ID: 18806302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bayesian estimation of cost-effectiveness from censored data.
    Heitjan DF; Kim CY; Li H
    Stat Med; 2004 Apr; 23(8):1297-309. PubMed ID: 15083484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parametric modelling of cost data in medical studies.
    Nixon RM; Thompson SG
    Stat Med; 2004 Apr; 23(8):1311-31. PubMed ID: 15083485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Semi-parametric regression models for cost-effectiveness analysis: improving the efficiency of estimation from censored data.
    Pullenayegum EM; Willan AR
    Stat Med; 2007 Jul; 26(17):3274-99. PubMed ID: 17309112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis for multinational clinical trials.
    Pinto EM; Willan AR; O'Brien BJ
    Stat Med; 2005 Jul; 24(13):1965-82. PubMed ID: 15803442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using multilevel models for assessing the variability of multinational resource use and cost data.
    Grieve R; Nixon R; Thompson SG; Normand C
    Health Econ; 2005 Feb; 14(2):185-96. PubMed ID: 15386660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the value for money of changing clinical practice change: a stochastic application in diabetes care.
    Hoomans T; Abrams KR; Ament AJ; Evers SM; Severens JL
    Med Care; 2009 Oct; 47(10):1053-61. PubMed ID: 19648827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach.
    Ramsey SD; Blough DK; Sullivan SD
    Med Care; 2008 May; 46(5):542-8. PubMed ID: 18438203
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating model uncertainty in cost-effectiveness analysis: a Bayesian model averaging approach.
    Negrín MA; Vázquez-Polo FJ
    J Health Econ; 2008 Sep; 27(5):1250-9. PubMed ID: 18490067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of an early interventional strategy in non-ST-elevation acute coronary syndrome based on the RITA 3 trial.
    Henriksson M; Epstein DM; Palmer SJ; Sculpher MJ; Clayton TC; Pocock SJ; Henderson RA; Buxton MJ; Fox KA
    Heart; 2008 Jun; 94(6):717-23. PubMed ID: 18032459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer.
    Tumeh JW; Shenoy PJ; Moore SG; Kauh J; Flowers C
    Am J Clin Oncol; 2009 Feb; 32(1):49-55. PubMed ID: 19194125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effective management of low-risk papillary thyroid carcinoma.
    Shrime MG; Goldstein DP; Seaberg RM; Sawka AM; Rotstein L; Freeman JL; Gullane PJ
    Arch Otolaryngol Head Neck Surg; 2007 Dec; 133(12):1245-53. PubMed ID: 18086967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden.
    Kobelt G; Berg J; Lindgren P; Jonsson B; Stawiarz L; Hillert J
    Mult Scler; 2008 Jun; 14(5):679-90. PubMed ID: 18566030
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal sample size determinations from an industry perspective based on the expected value of information.
    Willan AR
    Clin Trials; 2008; 5(6):587-94. PubMed ID: 19029207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global differences in patient characteristics, case management and outcomes in intracerebral hemorrhage: the Factor Seven for Acute Hemorrhagic Stroke (FAST) trial.
    Christensen MC; Broderick J; Vincent C; Morris S; Steiner T
    Cerebrovasc Dis; 2009; 28(1):55-64. PubMed ID: 19468216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis.
    Willan AR; Pinto EM; O'Brien BJ; Kaul P; Goeree R; Lynd L; Armstrong PW
    Health Econ; 2005 Apr; 14(4):327-38. PubMed ID: 15685652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A propensity score approach to estimating the cost-effectiveness of medical therapies from observational data.
    Mitra N; Indurkhya A
    Health Econ; 2005 Aug; 14(8):805-15. PubMed ID: 15791679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.